Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

Sarcura GmbH. (11/17/22). "Press Release: Sarcura Secures € 7M Seed Plus Funding to Revolutionize Cell Therapy Manufacturing". Klosterneuburg.

Organisations Organisation Sarcura GmbH
  Organisation 2 IST Cube Management GmbH
  Today Xista Science Ventures (fomerly IST cube)
  Group Xista Science Ventures (fomerly IST cube)
Products Product cell therapy manufacturing/processing technology
  Product 2 venture capital
Index term Index term Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube
Persons Person Buchmayr, Daniela (Sarcura 202211 CEO + Co-Founder)
  Person 2 Yang, Jerry (HCVC 202211 General Partner)

The Austrian deep tech startup Sarcura closes an oversubscribed €7M Seed Plus funding round to develop a next-generation cell therapy manufacturing platform.

The round was co-led by seed investors Lansdowne Investment Company Cyprus and IST Cube with participation from newly joined HCVC and tecnet equity. Besides returning seed investors Axilium Holding, Novacapital, and Nina Capital we are particularly happy to welcome newly joined European family offices with industrial biopharmaceutical backgrounds. The financing will fuel the development of Sarcura’s first system prototype.

“We are delighted to have successfully closed this funding round. It reflects the unmet need for breakthrough technologies to address the existing challenges in the manufacturing of cell therapies” says Daniela Buchmayr, Co-founder and CEO of Sarcura.

Engineered cell therapies bring hope to patients who lack alternatives. With more than 1400 CAR-T clinical trials ongoing, the advanced cell therapy industry has seen unprecedented growth, but the manufacturing of these lifesaving treatments remains a major bottleneck. 

“Scientists aim to identify and engineer the right cells, enhancing control while lowering manufacturing cost. Sarcura unites cutting-edge silicon technologies such as integrated photonics in microfluidic cartridges, to automate, miniaturize and bring real-time control to cell therapy manufacturing” says Daniela Buchmayr.

“Having spent the first 12 years of my career in semiconductors in Taiwan and Silicon Valley, I am really excited to have the chance to lead HCVC’s investment in Sarcura,” says Jerry Yang, General Partner at HCVC. “Sarcura is addressing a huge pain point in cell therapy by leveraging semiconductor MEMS technology. If successful, they could completely change the cancer treatment landscape. I’m looking forward to partnering with Daniela and her co-founders.” 

“The interdisciplinary team at Sarcura demonstrated their ability to advance developments at the intersection of biology and semiconductor technology. Enhancing the understanding of cell biology and solving biomanufacturing bottlenecks through advanced silicon-based technologies is key to translating scientific progress into therapeutic results for patients in the future. We are excited to continue and extend our support in this financing round together with the other investors in this round”, adds Florian Resch, Managing Partner at IST cube.

For more information, visit



is an Austrian deep-tech startup developing an instrument platform for the manufacturing of advanced cell therapies. Our platform combines silicon chip technology and microfluidic processing to enable real-time process control and manipulation on a cellular level, enabling a fully automated and modular manufacturing system. 

Lansdowne Investment Company Cyprus Limited

is an investment vehicle managed by Lansdowne Partners Austria GmbH which is an Austrian Alternative Investment Fund Manager with a strong focus on investing in and fostering European innovation. Lansdowne Partners Austria GmbH is part of the Lansdowne Partners group of companies.

IST cube

is an early-stage venture fund focusing on academic spin-offs and deep-tech startups rooted in science. The fund leads investment rounds in pre-seed and seed stages with the ability to follow on. IST cube supports portfolio companies with equity, know-how, and network. In addition, the fund has a strong partner in the Institute of Science and Technology Austria, which provides access to academic research and scientific infrastructure. 


is a thesis-driven venture capital firm that backs hard tech founders on a mission to digitize, automate and decarbonize the physical world. Currently investing out of its second fund, HCVC invests in early-stage startups in Europe and US, with first tickets ranging between 250k€~2.5M€. Notable portfolio companies include, Cowboy Bike, Caper Labs, Radian Aerospace, Automata, etc. HCVC also manages Hardware Club, the largest exclusive community in the world for hard tech startups, which today counts 1800+ founders.

tecnet equity

is a venture capital firm with EUR 50M under management. It finances new technology enterprises as well as companies with innovative business ideas. As an archetypal early-stage investor, tecnet has played an active part in the Austrian startup landscape for many years. With personal commitment, an international business network, and many years of experience, tecnet supports its investees in making their business successful.

Press Contact

Sarcura GmbH
Daniela Buchmayr, CEO

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Sarcura GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px

» top